drugset / Trial / NCT04768842

A Study of Two Different Formulations of LY3209590 in Healthy Participants

NCT04768842

Phase 1 Completed 50 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The main purpose of this study is to look at the amount of the study drug, LY3209590, that gets into the blood stream and how long it takes the body to get rid of LY3209590 when given as different formulations. The tolerability of LY3209590 will also be evaluated and information about any side effects experienced will be collected. The study will last up to 142 days.

Timeline

Start
2021-03-03
Primary completion
2021-09-03
Completion
2021-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Efsitora Alfa Protein / enzyme biologic Subcutaneous

Indications

No indication recorded.